Janice M Mehnert
Overview
Explore the profile of Janice M Mehnert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
89
Citations
4653
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fletcher K, Goodman R, Lawless A, Woodford R, Faak F, Tipirneni A, et al.
JAMA Dermatol
. 2025 Mar;
PMID: 40072456
No abstract available.
2.
Handel E, McKeown J, Wei J, Kankaria R, Burnette H, Johnson D, et al.
Eur J Cancer
. 2024 Dec;
215:115171.
PMID: 39667250
Immune checkpoint inhibitors (ICI) can achieve durable responses in patients with advanced melanoma, and results from clinical trials suggest cure may be possible for a subset of patients. Despite clinical...
3.
Hughes B, Guminski A, Bowyer S, Migden M, Schmults C, Khushalani N, et al.
J Am Acad Dermatol
. 2024 Sep;
92(1):68-77.
PMID: 39245360
Background: In the phase 2 EMPOWER-CSCC-1 study (NCT02760498), cemiplimab demonstrated antitumor activity against metastatic cutaneous squamous cell carcinoma (mCSCC) and locally advanced cutaneous squamous cell carcinoma (laCSCC). Objectives: To report...
4.
Miceli M, Boatwright C, Mehnert J
Cancer J
. 2024 Mar;
30(2):71-78.
PMID: 38527259
This review outlines the most up-to-date metastatic melanoma treatment recommendations and relevant risks for patients with solid organ transplants, patients with renal dysfunction, and patients with preexisting autoimmune conditions. These...
5.
Goodman R, Lawless A, Woodford R, Faak F, Tipirneni A, Patrinely J, et al.
JAMA Netw Open
. 2023 Aug;
6(8):e2327145.
PMID: 37535354
Importance: Anti-programmable cell death-1 (anti-PD-1) improves relapse-free survival when used as adjuvant therapy for high-risk resected melanoma. However, it can lead to immune-related adverse events (irAEs), which become chronic in...
6.
Chesney J, Puzanov I, Collichio F, Singh P, Milhem M, Glaspy J, et al.
J Immunother Cancer
. 2023 May;
11(5).
PMID: 37142291
Talimogene laherparepvec (T-VEC) plus ipilimumab has demonstrated greater antitumor activity versus ipilimumab alone, without additional toxicity, in patients with advanced melanoma. Here, we report the 5-year outcomes from a randomized...
7.
Ascierto P, Blank C, Eggermont A, Garbe C, Gershenwald J, Hamid O, et al.
J Transl Med
. 2023 Apr;
21(1):265.
PMID: 37072748
The Great Debate session at the 2022 Melanoma Bridge congress (December 1-3) featured counterpoint views from leading experts on five contemporary topics of debate in the management of melanoma. The...
8.
Spencer K, Portal D, Aisner J, Stein M, Malhotra J, Shih W, et al.
Oncotarget
. 2023 Apr;
14:302-315.
PMID: 37036756
Background: Overexpression of metabotropic glutamate receptor 1 (GRM1) has been implicated in the pathogenesis of multiple cancers. Riluzole, an inhibitor of glutamate release, showed synergistic antitumor activity in combination with...
9.
Silk A, Curti B, Bryan J, Saunders T, Shih W, Kane M, et al.
Front Oncol
. 2023 Feb;
13:1108341.
PMID: 36845705
Introduction: High-dose interleukin-2 (HD IL-2) and pembrolizumab are each approved as single agents by the U.S. F.D.A. for the treatment of metastatic melanoma. There is limited data using the agents...
10.
Baranda J, Diaz F, Rubinstein L, Shields A, Dayyani F, Mehta A, et al.
JNCI Cancer Spectr
. 2022 Dec;
7(1).
PMID: 36525371
Background: Disparities in cancer outcomes persist for underserved populations; one important aspect of this is limited access to promising early phase clinical trials. To address this, the National Cancer Institute-funded...